Skip to main content
Premium Trial:

Request an Annual Quote

BTIG Initiates Coverage of Cue Health With Buy Rating

NEW YORK – Investment bank BTIG initiated coverage of point-of-care diagnostic firm Cue Health on Tuesday with a Buy rating and a price target of $18 on its shares.

Analyst Mark Massaro wrote in a note that the San Diego-based firm is well positioned to take shares from reference labs and other point-of-care testing companies and will help "expand the $80 [billion] US lab testing pie."

Cue's handheld instrument "drives much better ease of use, particularly when used in people's homes," Massaro said, and BTIG models the company to exceed $500 million in revenue in its first full year, making it "one of the fastest growing diagnostic testing companies we've ever seen."

The firm's COVID-19 nucleic acid amplification test was the first molecular test to receive Emergency Use Authorization by the US Food and Drug Administration for home use without a prescription in March.

In his note, Massaro wrote that the home-use authorization of the Cue Health Monitoring System and the firm's COVID-19 test by the FDA, along with the test's ability to connect to smartphones, could "help drive new sources of applications, including telemedicine use (following receipt of a test result), virtual drug prescriptions, and more over time." 

Cue Health went public in September in a $200 million offering of 12.5 million shares priced at $16 per share. In its Form S-1 filing for its IPO, the company said it is developing other tests for its instrument, including five kits in late-stage technical development: influenza A/B, respiratory syncytial virus, fertility, pregnancy, and inflammation. 

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.